Phase 3 data for Pfizer's JAK inhibitor Xeljanz (tofacitinib) in ulcerative colitis has met both primary and secondary safety and efficacy endpoints. The data were presented at the European Crohn ...

Regulators in the US and EU have started a review of Pfizer's S1P receptor modulator etrasimod for people living with moderately-to-severely active ulcerative colitis (UC), with decisions expected ...

In December 2024, the American Gastroenterological Association (AGA) published an updated clinical guideline for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in ...